InVivo Therapeutics' (NVIV +18.6%) CEO tells shareholders the drug company's stock is...
InVivo Therapeutics' (NVIV +18.6%) CEO tells shareholders the drug company's stock is undervalued following a recent drop, and he expects the next six months to mark a "major inflection point" in growth. He expects FDA approval to start a study for the use of NVIV's biopolymer scaffolding to treat spinal cord injuries.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs